CN Patent

CN102697745A — 新颖的药物组合物

Assigned to NOVA LABORATORIES Sdn Bhd · Expires 2012-10-03 · 14y expired

What this patent protects

本发明公开了新颖的药物组合物及其制备方法，所述组合物包含3'-[(2Z)-[1-(3,4-二甲基苯基)-1,5-二氢-3-甲基-5-氧代-4H-吡唑-4-亚基]肼基]-2'-羟基-[1,1'-联苯]-3-羧酸双-(单乙醇胺)(艾曲波帕)。

USPTO Abstract

本发明公开了新颖的药物组合物及其制备方法，所述组合物包含3'-[(2Z)-[1-(3,4-二甲基苯基)-1,5-二氢-3-甲基-5-氧代-4H-吡唑-4-亚基]肼基]-2'-羟基-[1,1'-联苯]-3-羧酸双-(单乙醇胺)(艾曲波帕)。

Drugs covered by this patent

eltrombopag-olamine (ELTROMBOPAG OLAMINE)

Patent Metadata

Patent number: CN102697745A
Jurisdiction: CN
Classification: —
Expires: 2012-10-03
Drug substance claim: No
Drug product claim: No
Assignee: NOVA LABORATORIES Sdn Bhd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.